TCM Life Science Inc. — SEC Form D Filing
TCM Life Science Inc. filed an SEC Form D on October 26, 2026, reporting $17K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 26, 2026
- Amount reported
- $17K
- Round stage
- Pre-seed because the $16,666 raise represents initial formation capital for foundational administrative and preliminary laboratory setup.
- Industry
- Biotechnology
- Website
- https://www.tcmlifescience.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Pharmaceutical developers face significant technical challenges in standardizing and validating bioactive compounds derived from traditional natural sources for modern clinical applications.
Solution
TCM Life Science develops a biotechnology platform focused on isolating, standardizing, and advancing novel therapeutic compounds for drug discovery.
Why now
Advancements in mass spectrometry and genomic screening now enable precise characterization of complex biological formulations that were historically difficult to validate.
Source: SEC EDGAR Form D filing